Human Metabolome Technologies6090 
-0.66%24h
Human Metabolome Technologies (6090) Stock Overview
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
6090 Stock Information
Human Metabolome Technologies (6090) Price Chart
Human Metabolome Technologies Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $4.23 | N/A |
| Market Cap | $24.96M | N/A |
| Shares Outstanding | 5.90M | 0.08% |
| Employees | 57.00 | N/A |
| Shareholder Equity | 1.77B | 19.22% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | 0.09 | N/A |
| P/S Ratio | 2.74 | N/A |
| P/B Ratio | 0.01 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 0.0011 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $9.11M | N/A |
| Earnings | $2.00M | N/A |
| EPS | 48.39 | N/A |
| Earnings Yield | 11.45 | N/A |
| Gross Margin | 0.6617 | N/A |
| Operating Margin | 0.1624 | N/A |
| Net income margin | 0.2199 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $16.06M | N/A |
| Total Debt | $1.59M | N/A |
| Cash on Hand | $11.61M | N/A |
| Debt to Equity | 0.0021 | -25.26% |
| Cash to Debt | $7.31 | 13.35% |
| Current Ratio | $3.75 | 17.57% |
